Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
10-valent pneumococcal conjugate vaccine + diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type b vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination represents a pediatric immunization regimen designed to protect infants and young children against a broad spectrum of bacterial and viral pathogens. The 10-valent pneumococcal conjugate vaccine (PCV10), typically GSK's Synflorix, provides protection against ten serotypes of *Streptococcus pneumoniae* (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) using a combination of carrier proteins including non-typeable *Haemophilus influenzae* Protein D. The DTPa-IPV-Hib vaccine is a pentavalent combination (such as Infanrix-IPV+Hib) that protects against diphtheria, tetanus, pertussis (acellular), poliomyelitis (inactivated types 1, 2, and 3), and *Haemophilus influenzae* type b (Hib). These vaccines are often co-administered in a 2+1 or 3+1 schedule to simplify the vaccination process and ensure high coverage against invasive pneumococcal disease, meningitis, pneumonia, and other childhood infections.
- Brand names
- SynflorixInfanrix-IPV+Hib
- Other names
- PCV10 + DTPa-IPV-Hib10-valent pneumococcal conjugate vaccine + DTPa-IPV-Hib vaccine
02
Targets
PD (Protein D)TT (Tetanus toxoid)FHA (Filamentous hemagglutinin)PRN (Pertactin)SpCPS1 (Streptococcus pneumoniae capsular polysaccharide serotype 1)CPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)PPS5 (Streptococcus pneumoniae capsular polysaccharide serotype 5)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)
Beyond the preview
Go deeper on 10-valent pneumococcal conjugate vaccine + diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 10-valent pneumococcal conjugate vaccine + diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type b vaccine.